Chemotherapy and radiation regimens to breast cancer treatment induce changes in mRNA levels of renin-angiotensin system related genes in cardiac tissue

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 14, Issue 4, 2013, Pages 330-336

  Salata, Camila ^a   Ferreira Machado, Samara Cristina ^a,b   Mencalha, André Luiz ^a   De Andrade, Cherley Borba Vieira ^a   De Campos, Vera Maria Araújo ^a   Mandarim De Lacerda, Carlos Alberto ^a   Dealmeida, Carlos Eduardo ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Breast cancer; cardiotoxicity; chemotherapy; radiotherapy; RAS

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE; DOCETAXEL; MESSENGER RNA; RENIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CONTROLLED STUDY; ENZYME SYNTHESIS; FEMALE; GENE EXPRESSION REGULATION; HEART LEFT VENTRICLE; IMMUNOHISTOCHEMISTRY; MAST CELL; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RADIATION DOSE FRACTIONATION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BREAST CANCER; CARDIOTOXICITY; CHEMOTHERAPY; RADIOTHERAPY; RAS;

ANGIOTENSINOGEN; ANIMALS; FEMALE; GENE EXPRESSION REGULATION; MAMMARY NEOPLASMS, ANIMAL; MAST CELLS; MYOCARDIUM; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN; RENIN-ANGIOTENSIN SYSTEM; RNA, MESSENGER; STAINING AND LABELING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84889802626     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320312465218     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011 ; 61: 69-90
2. Yeah ETH, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy. Diagnosis, pathogenesis, and management. Circulation. 2004 ; 109: 3122-3131
3. Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. J Nat Cancer Inst. 2010 ; 102: 14-25
4. Liu H, Xiong M, Xia Y. Studies on pentoxifylline and tocopherol combination for radiation-induced heart disease in rats. Int J Radiat Oncol Biol Phys. 2009 ; 73: 1552-1559
5. Boerma M, Hauer-Jensen M. Preclinical research into basic mechanisms of radiation-induced heart disease. Cardiol Res Pract. 2010 ; 2011: 1-8
6. Boerma M, Wang J, Wondergem J, et al. Influence of mast cells on structural and functional manifestations of radiation-induced heart disease. Cancer Res. 2005 ; 65: 3100-3107 (Pubitemid 40524590)
7. Gaya AM, Ashford RF. Cardiac complications of radiation therapy. Clin Oncol. 2005 ; 17: 153-159 (Pubitemid 40468480)
8. Giordano SH, Kuo YF, Freeman JL, et al. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Nat Cancer Inst. 2005 ; 97: 419-424 (Pubitemid 40528604)
9. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006 ; 24: 5381-5387 (Pubitemid 46623169)
10. Lenihan DJ, Esteva FJ. Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer. Oncologist. 2008 ; 13: 1224-1334
11. Pal SK, Childs BH, Pegram M. Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer. Breast Cancer Res Treat. 2010 ; 119: 25-32
12. Schimmel KJM, Richel DJ, Van den Brink RBA, et al. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev. 2004 ; 30: 181-191 (Pubitemid 38418056)
13. Yeah ETH, Bickford CL. Cardiovascular complications of cancer therapy. J Am Coll Cardiol. 2009 ; 53: 2231-2247
14. Nakamae H, Tsumura K, Terada Y, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005 ; 104: 2492-2498 (Pubitemid 41691573)
15. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006 ; 114: 2474-2481 (Pubitemid 44901520)
16. Nair AP, Timoh T, Fuster V. Contemporary medical management of systolic heart failure. Circulation. 2012 ; 76: 268-277
17. Cat AND, Touyz RM. A new look at the renin-angiotensin system - Focusing on the vascular system. Peptides. 2011 ; 32: 2141-2150
18. Ferreira-Machado SC, Rocha NN, Mencalha AL, et al. Up-regulation of angiotensin-converting enzyme and angiotensin II type 1 receptor in irradiated rats. Int J Radiat Biol. 2010 ; 86: 880-887
19. Levy BI. How to explain the differences between renin angiotensin system modulators. Am J Hypertens. 2005 ; 18: 134S - 141S (Pubitemid 41206570)
20. Jin Z, Wang J, Zhang W, et al. Changes in cardiac structure and function in rats immunized by angiotensin type 1 receptor peptides. Acta Biochim Biophys Sin. 2011 ; 43: 970-976
21. Mello WC, Frohlich ED. On the local cardiac renin angiotensin system. Basic and clinical implications. Peptides. 2011 ; 32: 1774-1779
22. Reid AC, Silver RB, Levi R. Renin: At the heart of mast cell. Immunol Rev. 2007 ; 217: 123-140
23. US Food and Drug Administration. Guidance for industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers, www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf: (2005, accessed 15 June 2012).
24. Schultz-Hector S, Sund M, Thames HD. Fractionation response and repair kinetics of radiation-induced heart failure in the rat. Radiother Oncol. 1992 ; 23: 33-40
25. Krüse JJCM, Zurcher C, Strootman EG, et al. Structural changes in the auricles of the rat heart after local ionizing irradiation. Radiother Oncol. 2001 ; 58: 303-311 (Pubitemid 32181865)
26. Tokatli F, Uzal C, Doganay L, et al. The potential cardioprotective effects of amifostine in irradiated rats. Int J Radiat Oncol Biol Phys. 2004 ; 58: 1228-1234 (Pubitemid 38314808)
27. Altena R, Perik P, Veldhuisen DJV, et al. Cardiovascular toxicity caused by cancer treatment: Strategies for early detection. Lancet Oncol. 2009 ; 10: 391-399
28. Bader M, Peters J, Baltatu O, et al. Tissue renin-angiotensin systems: New insights from experimental animal models in hypertension research. J Mol Med. 2001 ; 79: 76-102 (Pubitemid 32285333)
29. Cummins PM. A new addition to the renin-angiotensin peptide family: proAngiotensin-12 (PA12). Cardiovasc Res. 2009 ; 82: 7-8
30. Robbins ME, Diz DI. Pathogenic role of the renin-angiotensin system in modulating radiation-induced late effects. Int J Radiat Oncol Biol Phys s. 2006 ; 64: 6-12 (Pubitemid 41831202)
31. Moulder JE, Fish BL, Cohen EP. Treatment of radiation nephropathy with ACE inhibitors and aII type-1 and type-2 receptor antagonists. Curr Pharm Des. 2007 ; 13: 1317-1325 (Pubitemid 46746369)
32. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med. 2008 ; 264: 224-236
33. Danser AH, van Kats JP, Admiraal PJ, et al. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension. 1994 ; 24: 37-48 (Pubitemid 24195402)
34. Shah AM. Paracrine modulation of heart cell function by endothelial cells. Cardiovasc Res. 1996 ; 31: 847-867 (Pubitemid 26188218)
35. Lüscher TF. Endothelial dysfunction: The role and impact of the renin-angiotensin system. Heart. 2000 ; 84: i20 - i22
36. Saijonmaa O, Nyman T, Stewen P, et al. Atorvastatin completely inhibits VEGF-induced ACE up-regulation in human endothelial cells. Am J Physiol Heart Circ Physiol. 2004 ; 286: H2096 - H2102
37. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003 ; 300: 1155-1159 (Pubitemid 36583102)
38. Darby SC, Cutter DJ, Boerma M, et al. Radiation-related heart disease: Current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010 ; 76: 656-665
39. Jelonek K, Walaszczyk A, Gabry D, et al. Cardiac endothelial cells isolated from mouse heart - a novel model for radiobiology. Acta Biochim Pol. 2011 ; 58: 397-404
40. Guo X, Lin G, Zhao H, et al. Inhibitory effects of docetaxel on expression of VEGF, bFGF and MMPs of LS174T cell. World J Gastroenterol. 2003 ; 9: 1995-1998 (Pubitemid 37168429)
41. Browder T, Butterfield CE, Kräling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000 ; 60: 1878-1886 (Pubitemid 30207647)
42. Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001 ; 61: 3369-3372 (Pubitemid 32695027)
43. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002 ; 13: 73-80 (Pubitemid 34436728)
44. Bader M, Peters J, Baltatu O, et al. Tissue renin-angiotensin systems: New insights from experimental animal models in hypertension research. J Mol Med. 2001 ; 79: 76-102 (Pubitemid 32285333)
45. Reid AC, Brazin JA, Morrey C, et al. Targeting cardiac mast cells: Pharmacological modulation of the local renin-angiotensin system. Curr Pharm Des. 2011 ; 17: 3744-3752
46. Kumar R, Singh VP, Baker KM. The intracellular rennin-angiotensin system in the heart. Curr Hypertens Rep. 2009 ; 11: 104-110
47. Xiao HD, Fuchs S, Campbell DJ, et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol. 2004 ; 165: 1019-1032 (Pubitemid 39129307)
48. Zablocki D, Sadoshima J. Knocking out angiotensin II in the heart. Curr Hypertens Rep. 2011 ; 13: 129-135
49. Kumar R, Boim MA. Diversity of pathways for intracellular angiotensin II synthesis. Curr Opin Nephrol Hypertens. 2009 ; 18: 33-39
50. Mello WC. Novel aspects of angiotensin II action in the heart. Implications to myocardial ischemia and heart failure. Regul Pept. 2011 ; 166: 9-14